This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tukysa (tucatinib + trastuzumab + capecitabine), from Seagen, for the treatment of advanced HER2-positive breast cancer.
Seagen Inc. announced data from the Phase III HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla)
Seattle Genetics, Inc. announced dosing of the first patient in HER2CLIMB-02, a randomized phase III clinical trial evaluating investigational agent...
This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with...
The National Institute of Health and Care Excellence (NICE) in a final decision recommended routine use of Kadcyla (ado-trastuzumab emtansine)...
Objective: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 – 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with...
The Phase II/III GATSBY trial, designed to support a new indication for Kadcyla (ado-trastuzumab emtansine) from Roche + ImmunoGen in...
The National Institute for Health and Care Excellence (NICE) in draft guidance has rejected Kadcyla (trastuzumab emtansine) or T-DM1, from...
Seattle Genetics, Inc.has announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for tucatinib, in combination...